Previous 10 | Next 10 |
2023-07-31 17:35:53 ET MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, after market close. The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $74.83M (+11.9% Y/Y). For further details see: ...
2023-07-25 08:11:12 ET Summary MiMedx has announced its intention to exit the knee osteoarthritis business to instead focus efforts on the high-growth Wound biologics market. The restructuring is expected to improve cash flow and profitability, supporting a positive long-term outl...
MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1...
2023-07-05 13:52:06 ET MiMedx ( NASDAQ: MDXG ) said Wednesday that it has appointed Doug Rice as the company's new chief financial officer. Rice will replace Pete Carlson, who has served in the CFO role since March 2020. Press Release . ...
MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has appointed Doug Rice as the Company’s Chief Financial Officer, effective today. Pete Carlson, who has served in that role si...
2023-06-27 03:18:02 ET MiMedx Group ( NASDAQ: MDXG ) stock price up 4.1% to $6.35 on Monday during late hours, the company filed Form 4 that shows CEO, Joseph H. Capper buying at total of 100k shares for $640K. On June 22 and June 23, 2023, he bought 57,975 and...
2023-06-20 16:54:49 ET MiMedx Group ( NASDAQ: MDXG ) said that it was pulling the plug on its knee osteoarthritis and regenerative medicine programs in order to focus on accelerating growth for its wound and surgical business. The wound care products company, which specializes i...
Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbanding Regenerative Medicine Business Unit Restructuring Expected to Generate Approximately $25 Million in Annualized Savings Raising Expectations to Deliver Mid-Teens Percentage Net Sales Growth D...
2023-05-23 08:29:22 ET CohBar ( CWBR ) +100% Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy. HeartCore Enterprises ( HTCR ) +59% Q1 earnings call rel...
2023-05-06 05:25:23 ET Summary Following the release of Q1 2023 results, MiMedx Group, Inc. shares are soaring on double-digit revenue growth and bottom line on track to turn a profit. MiMedx Group, Inc. is a Marietta, Georgia-based developer and distributor of placental tissue al...
News, Short Squeeze, Breakout and More Instantly...
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIET...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 3...